论文部分内容阅读
[目的]观察放射性125I粒子组织间植入联合GP方案(吉西他滨+顺铂)化疗治疗局部晚期非小细胞肺癌的疗效。[方法]治疗组33例患者联合GP方案化疗和125I粒子植入;对照组32例患者只接受单纯GP方案化疗,观察并比较两组患者的一般状况、近期疗效和不良反应。[结果]两组患者治疗后一般情况为:治疗组12例改善,12例稳定,9例进展;对照组7例改善,8例稳定,17例进展。两组比较差异有统计学意义(P=0.046)。治疗组CR5例,PR16例,SD9例,PD3例,有效率达63.6%;对照组CR2例,PR10例,SD12例,PD8例,有效率为37.5%,两组比较差异有统计学意义(P=0.022)。治疗组和对照组1年生存率分别为81.8%和71.9%(P>0.05)。两组骨髓抑制和胃肠道反应差异无统计学意义(P>0.05)。[结论]125I粒子组织间植入治疗联合化疗治疗局部晚期非小细胞肺癌有一定疗效,值得进一步推广。
[Objective] To observe the curative effect of radioactive 125I interstitial implantation combined with GP regimen (gemcitabine + cisplatin) in the treatment of locally advanced non-small cell lung cancer. [Method] Thirty-three patients in the treatment group were treated with GP regimen and 125I seeds. In the control group, 32 patients received only GP regimen. The general condition, short-term efficacy and adverse reactions were observed and compared between the two groups. [Results] After treatment, the general situation of two groups was improved in 12 cases in treatment group, 12 cases were stable and 9 cases were improved. In control group, 7 cases improved, 8 cases were stable and 17 cases progressed. The difference between the two groups was statistically significant (P = 0.046). The treatment group CR5, PR16, SD9 and PD3 cases, the effective rate was 63.6%; CR2 CR1, PR10 cases, SD12 cases, PD8 cases, the effective rate was 37.5%, the difference between the two groups was statistically significant (P = 0.022). The 1-year survival rates of the treatment group and the control group were 81.8% and 71.9%, respectively (P> 0.05). There was no significant difference in bone marrow suppression and gastrointestinal reaction between the two groups (P> 0.05). [Conclusion] There is a certain curative effect of 125I interstitial implantation therapy combined with chemotherapy in the treatment of locally advanced non-small cell lung cancer, which is worth further promotion.